Guideline for Management of Hirsutism in Reproductive‑Age Women

Initial Assessment & Decision‑Making

• Treatment choice should be guided by the degree of patient‑reported distress and cosmetic preferences rather than solely by objective hair‑growth scores (e.g., Ferriman‑Gallwey). 1, 2
• Pharmacologic therapy is indicated when cosmetic measures (shaving, plucking, waxing, bleaching) fail to relieve patient distress. 2, 3
• For mild hirsutism where patients are satisfied with cosmetic measures, pharmacologic treatment is not required. 1, 2
• Cosmetic methods are safe, inexpensive, and provide only temporary benefit; shaving does not increase hair growth rate or thickness. 1

First‑Line Pharmacologic Therapy: Oral Contraceptives (OCPs)

• Oral contraceptives are recommended as the initial monotherapy for most women with patient‑important hirsutism; anti‑androgens are added only after ≥6 months if response is inadequate. 2, 3
• OCPs lower hyperandrogenism by suppressing luteinizing hormone (reducing ovarian androgen production), increasing hepatic sex‑hormone‑binding globulin (raising androgen binding), modestly decreasing adrenal androgen secretion, and partially blocking androgen‑receptor binding. 1
• Additional OCP benefits include menstrual‑cycle regulation, endometrial protection, and reliable contraception. 1
• A minimum of 6 months of continuous OCP use is required before assessing efficacy, altering dose, switching agents, or adding another medication. 2, 3

Second‑Line Therapy: Adding an Anti‑androgen

• If hirsutism persists after ≥6 months of OCP monotherapy, an anti‑androgen should be added. 2, 4, 3

Spironolactone (Preferred Anti‑androgen)

• Recommended dosage: 100–200 mg daily, divided into two doses. 4
• Treatment response should be evaluated after a minimum of 12 months; earlier assessment may underestimate benefit. 4
• Strict contraception is mandatory for women of reproductive age because of teratogenic risk. 2, 3

Cyproterone Acetate (Where Available)

• Typical regimen: 50–100 mg daily on cycle days 5–15 combined with ethinyl‑estradiol 20–35 µg on days 5–25, or as a combined OCP (2 mg CPA + 35 µg EE). 4
• Not available in the United States. 4

Agents Not Recommended

• Flutamide should not be used as first‑line therapy because of rare but serious hepatotoxicity, including liver failure and death. 2, 3
• Topical anti‑androgens are not recommended for hirsutism. 2, 3

Alternative Pharmacologic Options

• In women who are not sexually active, have undergone permanent sterilization, or use long‑acting reversible contraception, either OCPs or anti‑androgens may be used as initial therapy. 2, 3
• Anti‑androgen monotherapy is contraindicated unless effective contraception is ensured. 2, 3
• Insulin‑lowering agents (e.g., metformin) are not recommended as sole therapy for hirsutism. 2, 3
• Glucocorticoids are not recommended for women without classic or non‑classic congenital adrenal hyperplasia; they may be considered only in NCCAH patients with suboptimal response to OCPs/anti‑androgens. 2, 3
• GnRH agonists are not recommended except for severe hyperandrogenemia (e.g., ovarian hyperthecosis) unresponsive to OCPs and anti‑androgens. 2, 3

Direct Hair‑Removal Methods

• Photoepilation (laser or intense pulsed light) is the preferred mechanical hair‑removal technique for women opting for hair removal. 4
• Adding topical eflornithine cream during photoepilation can accelerate the initial cosmetic response. 4
• For women with confirmed hyperandrogenemia undergoing hair removal, concurrent pharmacologic therapy should be added to minimize regrowth. 4

Combined Pharmacologic + Mechanical Approach

• When patient‑important hirsutism persists despite cosmetic measures, either pharmacologic therapy or direct hair‑removal methods may be chosen based on patient preference, treatable areas, and access/affordability; a combined approach is considered the most effective overall. 2, 3

Critical Pitfalls to Avoid

• Do not prescribe anti‑androgen monotherapy without ensuring effective contraception. 2, 3
• Do not modify the medication regimen or add agents before completing at least 6 months of therapy unless adverse effects mandate discontinuation. 2, 3
• Do not use flutamide as first‑line treatment because of hepatotoxic risk. 2, 3
• Do not discontinue treatment prematurely; visible improvement generally requires ≥6 months, and full assessment may need 6–12 months. 2, 3

Guideline Summary for Treatment of Hirsutism in Premenopausal Women

Assessment and Diagnostic Approach

• In women with moderate‑to‑severe hirsutism (modified Ferriman‑Gallwey score ≥ 4–8, ethnicity‑adjusted) or with sudden, rapidly progressive hair growth, menstrual dysfunction, obesity, or clitoromegaly, clinicians should test for elevated androgen levels. 5
• Women with isolated mild hirsutism or who are eumenorrheic with localized unwanted hair growth and a normal hirsutism score should not undergo routine androgen testing. 5

First‑Line Pharmacologic Therapy

• Oral contraceptives (OCPs) are the recommended initial pharmacologic treatment for the majority of premenopausal women with patient‑important hirsutism. 5
• OCPs lower free androgen concentrations by suppressing ovarian androgen production and increasing circulating sex‑hormone‑binding globulin (SHBG). 6
• Additional benefits of OCPs include menstrual cycle regulation, endometrial protection, and reliable contraception. 6
• All pharmacologic agents for hirsutism require a minimum trial of six months before dose adjustment, medication change, or addition of another agent. 5

Add‑On Antiandrogen Therapy (Second‑Line)

• If clinically significant hirsutism persists after ≥ 6 months of OCP monotherapy, an antiandrogen should be added. 7
• Spironolactone is the first‑line antiandrogen for reducing hirsutism when an add‑on is needed. 8
• Flutamide is not recommended because of a high risk of severe hepatotoxicity, including liver failure and death. 9
• Antiandrogen monotherapy is contraindicated unless effective contraception is ensured, due to teratogenic potential. 5

Alternative and Adjunctive Medical Options

• When OCPs are declined or contraindicated, metformin is the preferred agent for menstrual cycle regulation and improves insulin sensitivity, lowers triglycerides, and may delay progression to type 2 diabetes. 8
• Combined therapy with metformin plus an antiandrogen (e.g., spironolactone) provides superior biochemical improvement compared with either agent alone. 8
• Combined medical interventions are considered the most effective overall approach for hirsutism. 10

Direct Hair‑Removal Methods

• For patients opting for mechanical removal, laser or photo‑epilation is the preferred method and typically requires multiple treatment sessions for optimal permanent hair reduction. 5 [10]
• Topical eflornithine hydrochloride cream can be added to improve facial hirsutism and may be used as monotherapy for mild cases. 8
• Topical antiandrogen preparations are not recommended for hirsutism. 5
• Mechanical methods (shaving, waxing, plucking, electrolysis) should be used adjunctively; electrolysis offers permanent removal for localized areas. 8

Therapies Not Recommended

• Insulin‑lowering drugs are not indicated for hirsutism; monotherapy with an insulin sensitizer does not significantly improve hair growth. 5
• Glucocorticoids should not be used in women without classic or non‑classic congenital adrenal hyperplasia. 5
• GnRH agonists are reserved only for severe hyperandrogenemia (e.g., ovarian hyperthecosis) unresponsive to OCPs and antiandrogens. 5

Monitoring and Follow‑Up

• Treatment response should be evaluated every 3–6 months, with therapy adjustments based on symptom improvement and tolerability. 8
• Hirsutism severity should be tracked using the modified Ferriman‑Gallwey score; visible improvement generally requires ≥ 6 months of therapy. 8
• Metabolic screening (fasting glucose, oral glucose tolerance test, lipid profile) and cardiovascular risk assessment (blood pressure, weight, smoking status) should be performed regularly. 11
• Prior to initiating metformin, assess renal function; before spironolactone, evaluate serum potassium and renal status. Metformin must be discontinued before contrast‑enhanced imaging in patients with reduced renal function. 8 [11]

Critical Pitfalls to Avoid

• Do not postpone lifestyle modification (calorie‑restricted diet and regular exercise) – it is an essential foundation before pharmacologic therapy. 8
• Never prescribe antiandrogen monotherapy without ensuring effective contraception. 5
• Avoid changing or adding medications before the six‑month efficacy assessment period. 5
• Do not use flutamide as a first‑line agent because of its hepatotoxic risk. 9